Brisbane, Calif.-based biotech firm XDx Inc. on Wednesday announced that it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock.
XDx specializes in molecular diagnostics for the monitoring of transplant rejection and autoimmune diseases.
businessBusiness & Real Estate
Find out more at www.sfexaminer.com/join/